Turnover of the Active Fraction of IRS1 Involves Raptor-mTOR- and S6K1-Dependent Serine Phosphorylation in Cell Culture Models of Tuberous Sclerosis

REFERENCES

• Ali, S. M., and D. M. Sabatini. 2005. Structure of S6K1 determines if Raptor-mTOR or Rictor-mTOR phosphorylates its hydrophobic motif site. J. Biol. Chem. 280:19445–19448.
   PubMed Web of Science ®Google Scholar
• Boyle, W. J., and H. T. P. van der Geer. 1991. Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. Methods Enzymol. 201:110–149.
   PubMed Web of Science ®Google Scholar
• Carlson, C. J., M. F. White, and C. M. Rondinone. 2004. Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation. Biochem. Biophys. Res. Commun. 316:533–539.
   PubMed Web of Science ®Google Scholar
• Clark, S. F., S. Martin, A. J. Carozzi, M. M. Hill, and D. E. James. 1998. Intracellular localization of phosphoinositide 3-kinase and insulin receptor substrate-1 in adipocytes: potential involvement of a membrane skeleton. J. Cell Biol. 140:1211–1225.
   PubMedGoogle Scholar
• Clark, S. F., J.-C. Molero, and D. E. James. 2000. Release of insulin receptor substrate proteins from an intracellular complex coincides with the development of insulin resistance. J. Biol. Chem. 275:3819–3826.
   PubMedGoogle Scholar
• Corradetti, M. N., K. Inoki, N. Bardessy, R. A. DePinho, and K. L. Guan. 2004. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 18:1533–1538.
   PubMed Web of Science ®Google Scholar
• el-Hashemite, N., H. Zhang, E. P. Henske, and D. J. Kwiatkowski. 2003. Mutation in TSC2 and activation of mammalian target of rapamycin signaling pathway in renal angiomyolipoma. Lancet 361:1348–1349.
   PubMedGoogle Scholar
• Fisher, T. L., and M. F. White. 2004. Signaling pathways: the benefits of good communication. Curr. Biol. 14:R1005–R1007.
   PubMedGoogle Scholar
• Garami, A., F. J. Zwartkruis, T. Nobukuni, M. Joaquin, M. Roccio, H. Stocker, S. C. Kozma, E. Hafen, J. L. Bos, and G. Thomas. 2003. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11:1457–1466.
   PubMed Web of Science ®Google Scholar
• Giraud, J., R. Leshan, Y.-H. Lee, and M. F. White. 2004. Nutrient-dependent and insulin-stimulated phosphorylation of insulin receptor substrate-1 on serine 302 correlates with increased insulin signaling. J. Biol. Chem. 279:3447–3454.
   PubMed Web of Science ®Google Scholar
• Goncharova, E. A., D. A. Goncharova, A. Eszterhas, D. S. Hunter, M. K. Glassberg, R. S. Yeung, C. L. Walker, D. Noonan, D. J. Kwiatkowski, M. M. Chou, R. A. J. Panettieri, and V. P. Krymskaya. 2002. Tuberin regulates p70 S6 kinase activation and ribosomal protein s6 phosphorylation. J. Biol. Chem. 277:30958–30967.
   PubMed Web of Science ®Google Scholar
• Gual, P., T. Gremeaux, T. Gonzalez, Y. Le Marchand-Brustel, and J. F. Tanti. 2003. MAP kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor substrate-1 on serine residues 307, 612 and 632. Diabetologia 46:1532–1542.
   PubMed Web of Science ®Google Scholar
• Harrington, L. S., G. M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, H. Rebholz, J. Barnett, N. R. Leslie, S. Cheng, P. R. Shepherd, I. Gout, C. P. Downes, and R. F. Lamb. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213–223.
   PubMed Web of Science ®Google Scholar
• Harrington, L. S., G. M. Findlay, and R. F. Lamb. 2005. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci. 30:35–42.
   PubMed Web of Science ®Google Scholar
• Hellawell, G. O., G. D. Turner, D. R. Davies, R. Poulsom, S. F. Brewster, and V. M. Macaulay. 2002. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62:2942–2950.
   PubMed Web of Science ®Google Scholar
• Im, E., F. C. von Lintig, J. Chen, S. Zhuang, W. Qui, S. Chowdhury, P. F. Worley, G. R. Boss, and R. B. Pilz. 2002. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 21:6356–6365.
   PubMed Web of Science ®Google Scholar
• Inoki, K., T. Zhu, and K. L. Guan. 2003. Tsc2 mediates cellular energy response to control cell growth and survival. Cell 115:577–590.
   PubMed Web of Science ®Google Scholar
• Inoue, G., B. Cheatham, R. Emkey, and C. R. Kahn. 1998. Dynamics of insulin signaling in 3T3-L1 adipocytes. Differential compartmentalization and trafficking of insulin receptor substrate (IRS)-1 and IRS-2. J. Biol. Chem. 273:11548–11555.
   PubMed Web of Science ®Google Scholar
• Jaeschke, A., J. Hartkamp, M. Saitoh, W. Roworth, T. Nobukuni, A. Hodges, J. Sampson, G. Thomas, and R. Lamb. 2002. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol. 159:217–224.
   PubMedGoogle Scholar
• Kenerson, H. L., L. D. Aicher, L. D. True, and R. S. Yeung. 2002. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 62:5645–5650.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski, D. J., H. Zhang, J. L. Bandura, K. M. Heiberger, M. Glogauer, N. el-Hashemite, and H. Onda. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11:525–534.
   PubMed Web of Science ®Google Scholar
• Lee, Y. H., J. Giraud, R. J. Davis, and M. F. White. 2003. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J. Biol. Chem. 278:2896–2902.
   PubMed Web of Science ®Google Scholar
• Li, Y., K. Inoki, and K. L. Guan. 2004. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol. Cell. Biol. 24:7965–7975.
   PubMed Web of Science ®Google Scholar
• Li, Y., T. J. Soos, X. Li, J. Wu, M. DeGennaro, X. Sun, D. R. Littman, M. J. Birnbaum, and R. D. Polakiewicz. 2004. Protein Kinase C θ inhibits insulin signaling by phosphorylating IRS1 at Ser1101. J. Biol. Chem. 279:45304–45307.
   PubMed Web of Science ®Google Scholar
• Long, X., Y. Lin, S. Ortiz-Vega, K. Yonezawa, and J. Avruch. 2005. Rheb binds and regulates the mTOR kinase. Curr. Biol. 15:702–713.
   PubMed Web of Science ®Google Scholar
• Luo, J., S. J. Field, J. Y. Lee, J. A. Engelman, and L. C. Cantley. 2005. The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J. Cell Biol. 170:455–464.
   PubMedGoogle Scholar
• Ma, L., J. Teruya-Feldstein, N. Behrendt, Z. Chen, T. Noda, O. Hino, C. Cordon-Cardo, and P. P. Pandolfi. 2005. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Cell 19:1779–1786.
   Google Scholar
• Manning, B. D. 2004. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167:399–403.
   PubMed Web of Science ®Google Scholar
• Manning, B. D., M. N. Logsdon, A. I. Lipovsky, D. Abbott, D. J. Kwiatkowski, and L. C. Cantley. 2005. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 19:1773–1778.
   PubMed Web of Science ®Google Scholar
• Onda, H., P. B. Crino, H. Zhang, R. D. Murphey, L. Rastelli, B. E. Gould-Rothberg, and D. J. Kwiatkowski. 2002. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol. Cell Neurosci. 21:561–574.
   PubMed Web of Science ®Google Scholar
• O'Reilly, K. E., F. Rojo, Q. B. She, D. Solit, G. B. Mills, D. Smith, H. Lane, F. Hofmann, D. J. Hicklin, D. L. Ludwig, J. Baselga, and N. Rosen. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500–1508.
   PubMed Web of Science ®Google Scholar
• Radimerski, T., J. Montagne, M. Hemmings-Mieszczak, and G. Thomas. 2002. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev. 16:2627–2632.
   PubMed Web of Science ®Google Scholar
• Reiss, K., J. Y. Wang, G. Romano, F. B. Furnari, W. K. Cavenee, A. Morrione, X. Tu, and R. Baserga. 2000. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 19:2687–2694.
   PubMedGoogle Scholar
• Reiss, K., J. Y. Wang, G. Romano, X. Tu, F. Peruzzi, and R. Baserga. 2001. Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells. Oncogene 20:490–500.
   PubMed Web of Science ®Google Scholar
• Sarbassov, D. D., S. M. Ali, S. Sengupta, J. H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard, and D. M. Sabatini. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22:159–168.
   PubMed Web of Science ®Google Scholar
• Shah, O. J., and T. Hunter. 2004. Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex. J. Biol. Chem. 279:20816–20823.
   PubMed Web of Science ®Google Scholar
• Shah, O. J., and T. Hunter. 2005. Tuberous sclerosis and insulin resistance: unlikely bedfellows reveal a TORrid affair. Cell Cycle 4:122–127.
   Google Scholar
• Shah, O. J., S. R. Kimball, and L. S. Jefferson. 2000. Among translational effectors, p70S6k is uniquely sensitive to inhibition by glucocorticoids. Biochem. J. 347:389–397.
   PubMed Web of Science ®Google Scholar
• Shah, O. J., Z. Wang, and T. Hunter. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14:1650–1656.
   PubMed Web of Science ®Google Scholar
• Shaw, R. J., N. Bardessy, B. D. Manning, L. Lopez, M. Kosmatka, R. A. DePinho, and L. C. Cantley. 2004. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:1–9.
   PubMedGoogle Scholar
• Takano, A., I. Usui, T. Haruta, J. Kawahara, T. Uno, M. Iwata, and M. Kobayashi. 2001. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol. Cell. Biol. 21:5050–5062.
   PubMed Web of Science ®Google Scholar
• Tee, A. R., B. D. Manning, P. P. Roux, L. C. Cantley, and J. Blenis. 2003. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13:1259–1268.
   PubMed Web of Science ®Google Scholar
• Tremblay, F., A. M. Gagnon, A. Veilleux, A. Sorisky, and A. Marette. 2005. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 146:1328–1337.
   PubMed Web of Science ®Google Scholar
• Tzatsos, A., and K. V. Kandror. 2006. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via Raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol. Cell. Biol. 26:63–76.
   PubMed Web of Science ®Google Scholar
• Uhlmann, E. J., W. Li, D. K. Scheidenhelm, C.-L. Gau, F. Tamanoi, and D. H. Gutmann. 2004. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia 47:180–188.
   PubMedGoogle Scholar
• Um, S. H., F. Frigerio, M. Watanabe, F. Picard, M. Jaoquin, M. Sticker, S. Fumagalli, P. R. Allegrini, S. C. Kozma, J. Auwerx, and G. Thomas. 2004. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200–205.
   PubMed Web of Science ®Google Scholar
• Zhang, H., G. Cicchetti, H. Onda, H. B. Koon, K. Asrican, N. Bajraszewski, F. Vazquez, C. L. Carpenter, and D. J. Kwiatkowski. 2003. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Investig. 112:1223–1233.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., X. Gao, L. J. Saucedo, B. Ru, B. A. Edgar, and D. Pan. 2003. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5:578–581.
   PubMed Web of Science ®Google Scholar